ADVM – adverum biotechnologies, inc. (US:NASDAQ)
Stock Stats
News
11/5
11:19 am
advm
Low
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
11/4
07:54 pm
advm
Low
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/4
05:20 pm
advm
Low
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
11/4
04:46 pm
advm
Low
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
11/4
04:39 pm
advm
Low
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
8/12/2024
04:05 pm
advm
4.2%
BEAT
5/9/2024
04:05 pm
advm
-3.2%
MISS
11/9/2023
04:05 pm
advm
2.9%
MISS
11/5
11:17 am
Maintains
Sector Perform
Sector Perform
RBC Capital
Low
1.0%
11/5
11:17 am
Maintains
Sector Perform
Sector Perform
RBC Capital
Low
1.0%
8/13
02:22 pm
Reiterates
Buy
Buy
HC Wainwright
Low
2.1%
8/13
12:24 pm
Maintains
Sector Perform
Sector Perform
RBC Capital
0.0%
8/13
12:24 pm
Maintains
Sector Perform
Sector Perform
RBC Capital
0.0%
11/4
04:45 pm
advm
Low
Form 10-Q Adverum Biotechnologies, For: Sep 30
11/4
04:43 pm
advm
Low
Form 8-K Adverum Biotechnologies, For: Nov 04
10/31
12:41 pm
advm
Low
Form SCHEDULE 13G Adverum Biotechnologies, Filed by: FRANKLIN RESOURCES INC
10/30
09:35 pm
advm
Medium
Form SC 13G Adverum Biotechnologies, Filed by: Stern Augustus
10/23
01:34 pm
advm
Low
Form SC 13G Adverum Biotechnologies, Filed by: Principia Wealth Advisory, LLC
Show more
Top News Gainers
3/12 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 30.8%
5/16 Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD 26.0%
2/10 Form 424B5 Adverum Biotechnologies, 23.8%
7/8 Adverum Biotechnologies to Present Data at Upcoming Conferences 22.5%
2/9 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. 21.0%
3/18 Form 4 Adverum Biotechnologies, For: Mar 17 Filed by: PATTERSON LEONE D 17.0%
10/11 Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 15.1%
3/19 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.2%
3/25 Form 4 Adverum Biotechnologies, For: Mar 20 Filed by: PATTERSON LEONE D 9.2%
10/31 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates 8.8%
Top News Decliners
3/11 Adverum Biotechnologies Announces Data Presentations at ARVO 2020 -13.8%
3/16 Adverum Biotechnologies Inc (NASDAQ: ADVM) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating on the stock. -13.2%
8/1 Adverum Biotechnologies Announces Board and Senior Management Changes -12.6%
2/10 Adverum Biotechnologies Inc (NASDAQ: ADVM) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock, up previously from $10.00. -11.8%
4/20 Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors -11.6%
3/5 Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update -10.7%
9/13 Adverum Biotechnologies Inc (NASDAQ: ADVM) had its price target lowered by analysts at Chardan Capital from $10.00 to $6.00. They now have a "neutral" rating on the stock. -10.4%
4/29 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
3/11 Adverum Biotechnologies Inc (NASDAQ: ADVM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -9.4%
3/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM -9.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3